SCHEMBL3752476

SCHEMBL3752476

COC(=O)C(C)(C)NC(=O)c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.53
CNR2 P34972 5/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
LMNA P02545 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
CYP1A2 P05177 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
PTGS2 P35354 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
ELANE P08246 1/20 0.45
FLT1 P17948 1/20 0.45
FLT4 P35916 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12881814 0.84 GAA (0.52) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL16810731 0.83 OGG1 (0.47) POLBSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL3755534 0.82 POLB (0.56) POLBSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL8084321 0.81 POLB (0.54) POLBSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL2949568 0.80 POLB (0.61) POLBSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL1761361 0.79 HRH3 (0.50) POLBCNR2SMN1; SMN2NPC1RAB9A
SCHEMBL11463830 0.77 SMN1; SMN2 (0.64) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL12024323 0.77 POLB (0.53) POLBSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL27388247 0.76 HPGD (0.51) CNR2SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL11921043 0.76 POLB (0.49) POLBSMN1; SMN2NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2212334-B1 PROTEASOME INHIBITORS MILLENNIUM PHARM INC (US) 2012-08-15 EP disclosed
US-7838673-B2 Proteasome inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-11-23 US disclosed
US-20090099132-A1 Proteasome inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099132-A1 Proteasome inhibitors PSMB5, PSMG3, PSMB1 POLB 836/4885CNR2 4760/4885SMN1; SMN2 1033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.